Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Mild Cognitive Impairment
Interventions: Online Gameplay Intervention, Waitlist control; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Reward Value Level
Interventions: Socially Evaluated Cold Pressor Task (SECPT), Non-Stressful Control Task; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Follicular Lymphoma, Small Lymphocytic Lymphoma
Interventions: Ublituximab, Umbralisib; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee

Conditions: Multiple Myeloma
Interventions: Daratumumab 16 mg/kg (Part 1), Daratumumab 8 mg/kg (Part 1), Methylprednisolone, Acetaminophen, Diphenhydramine, Daratumumab (Part 2); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more

Conditions: Obesity, Heart Failure
Interventions: PET (Positron Emission Tomography), Echocardiogram, ^15O-water, 1-^11C-palmitate, 1-^11C-glucose; Procedure · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: Use of smartphone app; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Carcinoma, Breast Neoplasm
Interventions: Ultrasound; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, mRNA-1405, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more

Conditions: Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
Interventions: Elacestrant, Abemaciclib; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: Fullerton, California • Los Angeles, California • Urbana, Illinois + 8 more

Conditions: Idiopathic Short Stature
Interventions: No treatment is given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 43 participants
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Orange, California • Columbia, Maryland

Conditions: Alzheimer Disease
Interventions: Simufilam; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 51 Years to 89 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 107
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: LY3857210, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 28
States / cities: Chandler, Arizona • Phoenix, Arizona • Riverside, California + 23 more

Conditions: Sickle Cell Disease
Interventions: Intravenous citrulline; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 6 Years to 50 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Cutaneous T Cell Lymphoma
Interventions: Placebo, CD11301 0.03%, CD11301 0.06%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Orange, California • Palo Alto, California • Farmington, Connecticut + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: SomaSignal Informed Medical Management SSCVD, Standard of Care; Diagnostic Test · Other
Lead sponsor: Emory University; Other
Eligibility: 40 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia

Conditions: Myotonic Dystrophy Type 2, Myotonic Dystrophy Type 1
Interventions: Non-interventional study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cystic Fibrosis
Interventions: VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more

Conditions: Knee Osteoarthritis
Interventions: ENGAGE; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Interventions: Blood Draw; Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 20 more

Conditions: Asthma, Asthma Attack, Asthma, Allergic
Interventions: Spirobank Smart spirometer; Device
Lead sponsor: VitalFlo Inc.; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Cancer
Interventions: LY2603618, Desipramine, Pemetrexed, Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Neurofibromatosis Type 1, Neurofibroma
Interventions: Arm 1; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 120 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ulcerative Colitis
Interventions: iPhone Application; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Surgery
Interventions: COMPAS Participants; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

GAMES Intervention in MCI (Mild Cognitive Impairment)

Stress and Anxiety Effects on Valuation

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Sex and Obesity: Effects on Heart Failure Study

Feasibility of Use of BariCare App in Pre-bariatric Surgery.

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

Open-label Extension for Phase 3 Clinical Trials of Simufilam

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Occupational Therapy-Delivered Cognitive Behavioral Therapy for Symptomatic Knee Osteoarthritis

Prospective Clinicogenomic Program

Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

Improving Knowledge of Medication in Ulcerative Colitis With an Iphone Application

Collecting Outcomes and Managing Pain After Surgery